JP2015221782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015221782A5 JP2015221782A5 JP2015090741A JP2015090741A JP2015221782A5 JP 2015221782 A5 JP2015221782 A5 JP 2015221782A5 JP 2015090741 A JP2015090741 A JP 2015090741A JP 2015090741 A JP2015090741 A JP 2015090741A JP 2015221782 A5 JP2015221782 A5 JP 2015221782A5
- Authority
- JP
- Japan
- Prior art keywords
- film
- weight
- coated
- tablet according
- binder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007941 film coated tablet Substances 0.000 claims 5
- 239000003826 tablet Substances 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims 2
- 229960001951 montelukast sodium Drugs 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 229910001929 titanium oxide Inorganic materials 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229960002900 Methylcellulose Drugs 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229940069328 Povidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015090741A JP2015221782A (ja) | 2014-04-28 | 2015-04-27 | モンテルカストナトリウム含有製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014092504 | 2014-04-28 | ||
| JP2014092504 | 2014-04-28 | ||
| JP2015090741A JP2015221782A (ja) | 2014-04-28 | 2015-04-27 | モンテルカストナトリウム含有製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015221782A JP2015221782A (ja) | 2015-12-10 |
| JP2015221782A5 true JP2015221782A5 (hr) | 2016-10-20 |
Family
ID=54785031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090741A Pending JP2015221782A (ja) | 2014-04-28 | 2015-04-27 | モンテルカストナトリウム含有製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2015221782A (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018147353A1 (ja) * | 2017-02-09 | 2018-08-16 | 日本新薬株式会社 | 錠剤 |
| JP7166754B2 (ja) | 2017-11-22 | 2022-11-08 | 沢井製薬株式会社 | ダサチニブ無水物含有製剤 |
| CN111110679A (zh) * | 2018-10-31 | 2020-05-08 | 长春海悦药业股份有限公司 | 一种含有孟鲁司特钠的药物组合物 |
-
2015
- 2015-04-27 JP JP2015090741A patent/JP2015221782A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122460T1 (el) | ΔΙΣΚΙΟ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 7- [4- (4-ΒΕΝΖΟ [b] ΘΕΙΟΦΑΙΝ-4-ΥΛΟ-ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΒΟΥΤΟΞΥ]-1Η-ΚΙΙΝΟΛΙΝ-2-ΟΝΗ Ή ΑΛΑΣ ΑΥΤΗΣ | |
| WO2019060322A3 (en) | HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF | |
| HRP20190069T1 (hr) | Farmaceutske formulacije koje sadrže ccr3 antagoniste | |
| JP2019151657A5 (hr) | ||
| JP2009537538A5 (hr) | ||
| RS51330B (en) | STABLE PHARMACEUTICAL FORMULATIONS OF MONTELUKAST SODIUM | |
| JP2015221782A5 (hr) | ||
| JP2018197270A5 (hr) | ||
| RU2014138035A (ru) | Твердая фармацевтическая композиция, содержащая 1-(3-(2-(1-бензотиофен-5-ил)этокси)пропил)азетидин-3-ол или его соль | |
| FI3702351T3 (fi) | MEK-inhibiittorin käsittävä koostumus | |
| JP2019513800A5 (hr) | ||
| RU2016150178A (ru) | Твёрдая дисперсия аллисартана изопроксила и фармацевтическая композиция | |
| JP2016135782A5 (hr) | ||
| MX2021007061A (es) | Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina. | |
| JP2017523149A5 (hr) | ||
| JP2019504848A5 (hr) | ||
| JP2019513801A5 (hr) | ||
| JP2015508411A5 (hr) | ||
| BR112015023381A2 (pt) | composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido | |
| JP2017537883A5 (hr) | ||
| JP2016013980A5 (hr) | ||
| JOP20170197B1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
| EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
| JP2015129175A5 (hr) | ||
| JP2015221782A (ja) | モンテルカストナトリウム含有製剤 |